Mycophenolate Mofetil and Plasmapheresis: A Treatment Option for Severe Insulin Resistance caused by Insulin Antibodies
Open Access
- 13 March 2021
- journal article
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 7 (5) , 307-309
Abstract
No abstract availableKeywords
Funding Information
- Endocrine Society
This publication has 15 references indexed in Scilit:
- Extreme Insulin Resistance From Insulin Antibodies (Not Insulin Receptor Antibodies) Successfully Treated With Combination Immunosuppressive TherapyDiabetes Care, 2016
- Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodiesDiabetologia, 2010
- Treatment of Type B Insulin Resistance: A Novel Approach to Reduce Insulin Receptor AutoantibodiesThe Journal of Clinical Endocrinology & Metabolism, 2010
- Severe insulin resistance due to anti‐insulin antibodies: response to plasma exchange and immunosuppressive therapyDiabetic Medicine, 2009
- Severe insulin resistance secondary to insulin antibodies: successful treatment with the immunosuppressant MMFPediatric Diabetes, 2008
- Immunological Responses to Exogenous InsulinEndocrine Reviews, 2007
- The model for end-stage liver disease (MELD)Hepatology, 2007
- Hypoglycemia and Hyperglycemia Due to Insulin Antibodies against Therapeutic Human Insulin: Treatment with Double Filtration Plasmapheresis and PrednisoloneThe American Journal of the Medical Sciences, 2005
- Mechanism of Action of Mycophenolate MofetilTherapeutic Drug Monitoring, 1995
- Clinical Significance of Insulin Antibodies in Insulin-Treated Diabetic PatientsDiabetes Care, 1989